TITLE

INNEXUS UNVEILS DXL625 ANTI-CD20 MONOCLONAL ANTIBODY

PUB. DATE
October 2007
SOURCE
Worldwide Biotech;Oct2007, Vol. 19 Issue 10, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the announcement by InNexus Biotechnology Inc. that significant enhancement of critical performance factors for many monoclonal antibodies appears possible through their Dynamic Cross Linking technology. Findings showed that DXL625, the company's first product candidate, can have greater potency, binding affinity, and related characteristics than the parent compound. The results were said to be presented as part of the Cancer Track at the IBC Life Science Drug Discovery and Development of Innovative Therapeutics Conference.
ACCESSION #
26715138

 

Related Articles

  • Cross-linking Antibodies. Proffitt, Allison // Bio-IT World;Sep2007, Vol. 6 Issue 7, p12 

    The article focuses on the monoclonal antibody DXL625 (CD20) being developed by InNexus Biotechnology for the treatment of non-Hodgkin's lymphoma. InNexus has received $2 million for DXL625 and its total purchase price may be increased to $30 million if certain conditions are fulfilled. The...

  • Monoclonal Antibody-Based Targeted Therapy in Breast Cancer. Altundag, Kadri; Esteva, Francisco J.; Arun, Banu // Current Medicinal Chemistry - Anti-Cancer Agents;Mar2005, Vol. 5 Issue 2, p99 

    Advances in molecular biology have identified tumor markers that not only predict prognosis and therapeutic response but may also function as potential therapeutic targets. Activated growth factor receptors induce breast cancer cells to proliferate, invade, and metastasize in experimental...

  • Next-generation monoclonals less profitable than trailblazers? Mitchell, Peter // Nature Biotechnology;Aug2005, Vol. 23 Issue 8, p906 

    The article reports that a new study has suggested that therapeutics based on monoclonal antibodies (mAbs) are far more likely to be commercially successful than their small-molecule predecessors. For the next generation of mAb-involved biotech companies, it may not be as easy as before to...

  • Polyclonal antibodies step out of the shadows. Waltz, Emily // Nature Biotechnology;Oct2006, Vol. 24 Issue 10, p1181 

    The article reports on the emergence of therapeutic polyclonal antibodies as clinical medicine. The first recombinant human polyclonal antibodies to enter the clinic could spearhead a new generation of antibody treatments. Moreover, the new-generation antibodies that are taking advantage of the...

  • European patents for DXL technology.  // Medical Device Daily;10/31/2008, Vol. 12 Issue 213, p8 

    The article reports that patent grants were given to InNexus Biotechnology for its next generation of monoclonal antibodies using its Dynamic Cross Linking (DXL) technology. The patents titled "Method of Affinity Cross-Linking Biologically Active, Immunogenic Peptides to Antibodies" were granted...

  • Anti-IGF-1 receptor antibody figitumumab active in sarcoma, Ewing's sarcoma.  // Hem/Onc Today;1/25/2010, Vol. 11 Issue 2, p51 

    The article focuses on a study that found that figitumumab, a fully human IgG2 monoclonal antibody targeting the insulin-like growth factor-1 receptor, was found to be well tolerated and demonstrated antitumor activity.

  • The growth and potential of human antiviral monoclonal antibody therapeutics. Marasco, Wayne A.; Jianhua Sui // Nature Biotechnology;Dec2007, Vol. 25 Issue 12, p1421 

    Monoclonal antibodies (mAbs) have long provided powerful research tools for virologists to understand the mechanisms of virus entry into host cells and of antiviral immunity. Even so, commercial development of human (or humanized) mAbs for the prophylaxis, preemptive and acute treatment of viral...

  • InNexus and Corixa to develop monoclonal antibodies.  // PharmaWatch: Cancer;October 2003, Vol. 2 Issue 10, p17 

    Reports on an antibody research, development and license agreement between InNexus Biotechnology and Corixa Corp. Terms of the agreement; Development of the anti-tumor activity of selected antibody leads.

  • monoclonal antibody.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1486 

    An encyclopedia entry for "monoclonal antibody," which refers to the antibody which is specific to a certain antigen, is presented.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics